Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 5, 2007, Pages 2254-2259

  Ishikawa, Kohei ^a   Kondo, Mineo ^a   Ito, Yasuki ^a   Kikuchi, Masato ^a   Nishihara, Hiroaki ^a   Piao, Chang Hua ^a   Sugita, Tadasu ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOCYANINE GREEN; VERTEPORFIN; DIAGNOSTIC AGENT; PHOTOSENSITIZING AGENT;

AGED; ANALYTIC METHOD; ARTICLE; CHOROID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTRORETINOGRAM; FEMALE; HUMAN; MACULAR THICKNESS; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RETINA MACULA LUTEA; STATISTICAL SIGNIFICANCE; THICKNESS; CIRCULATION; ELECTRORETINOGRAPHY; FLUORESCENCE ANGIOGRAPHY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VASCULARIZATION; VISUAL ACUITY;

AGED; BLOOD CIRCULATION; CHOROID; CHOROIDAL NEOVASCULARIZATION; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 34250157721     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1277     Document Type: Article

References (29)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
3. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial. VIP report 1. Ophthalmology. 2001;108:841-852.
4. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
5. Japanese Age-Related Macular Degeneration Tial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049-1061.
6. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-134.
7. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683-696.
8. Palmowski AM, Allgayer R, Heinemann-Vernaleken B, Ruprecht KW. Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry. Ophthalmology. 2002;109:1788-1792.
9. Moschos MN, Panayotidis D, Moschos MM, Bouros C, Theodossiadis PG, Theodossiadis GP. A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol. 2003;13:461-467.
10. Rüther K, Breidenbach K, Schwartz R, Hassenstein A, Richard G. Testing central retinal function with multifocal electroretinography before and after photodynamic therapy. Ophthalmologe. 2003;100:459-464.
11. Jiang L, Jin C, Wen F, Huang S, Wu D, Wu L. The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. Doc Ophthalmol. 2003;107:165-170.
12. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol. 2004;137:826-833.
13. Moschos MM, Panayotidis D, Theodossiadis G, Moschos M. Assessment of macular function by multifocal electroretinogram in age-related macular degeneration before and after photodynamic therapy. J Fr Ophtalmol. 2004;27:1001-1006.
14. Mennel S, Meyer CH. Transient visual disturbance after photodynamic therapy. Am J Ophthalmol. 2005;139:748-749.
15. Miyake Y, Shiroyama N, Ota I, Horiguchi M. Oscillatory potentials in electroretinograms of the human macular region. Invest Ophthalmol Vis Sci. 1988;29:1631-1635.
16. Miyake Y. Studies of local macular ERG. Acta Soc Ophthalmol Jpn. 1988;92:1418-1449.
17. Miyake Y, Shiroyama N, Ota I, Horiguchi M. Local macular electroretinographic responses in idiopathic central serous chorioretinopathy. Am J Ophthalmol. 1988;106:546-550.
18. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina. 2003;23:159-165.
19. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147-2154.
20. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002;134:566-576.
21. Miner JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
22. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
23. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999;106:1915-1923.
24. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
25. Tzekov R, Lin T, Zhang KM, et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci. 2006;47:377-385.
26. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.
27. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
28. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology. 2003;110:1306-1314.
29. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.